Key result
Plasma LDL-cholesterol was independently associated with CAC score =0 (OR 0.67; 95% CI 0.48-0.92), CAC score >100 (OR 1.59), and high femoral IMT (OR 1.89) in intermediate-risk individuals.
Why the study?
To identify noninvasive vascular biomarkers suitable for detecting intermediate-risk individuals who might benefit from lipid-lowering treatment in primary prevention.
Is plasma LDL-cholesterol associated with noninvasive vascular biomarkers in asymptomatic individuals at intermediate cardiovascular risk?
Cross-Sectional (n=260)
Is plasma LDL-cholesterol associated with noninvasive vascular biomarkers in asymptomatic individuals at intermediate cardiovascular risk?
In asymptomatic intermediate-risk individuals, LDL-cholesterol is associated with CAC scores and femoral IMT, supporting the use of these biomarkers to guide lipid-lowering therapy decisions.
Several noninvasive vascular biomarkers have been suggested for improving the risk stratification for atherothrombotic events. To identify biomarkers suitable for detecting intermediate-risk individuals who might benefit from lipid-lowering treatment (L-LT) in primary prevention, the present study tested the association of plasma LDL-cholesterol with coronary artery calcification (CAC) Agatston score, high carotid and femoral intima-media thickness (IMT), low carotid distensibility and high carotid-femoral pulse-wave velocity in 260 asymptomatic individuals at intermediate cardiovascular risk and free of diabetes and L-LT. High or low vascular biomarkers were considered when their value was above the 95th or below the 5th percentile, respectively, of the distribution in the healthy or in the study population. LDL-cholesterol was independently associated with the CAC score =0 (OR 0.67; 95%CI 0.48-0.92, P=0.01), CAC score >100 (1.59; 1.08-2.39, P=0.01) and with high femoral IMT (1.89; 1.19-3.06, P<0.01), but not with other biomarkers. Our data confirm that in the presence of CAC score =0 in individuals at intermediate risk, L-LT can be avoided, while it should be used in those with CAC score >100. Femoral artery IMT could represent a useful biomarker for decision regarding L-LT, however the reference values according to sex and age should be established in a large healthy population
No takes yet. Share an insight, caveat, or question.
Kozàkovà et al. (2023) conducted a cross-sectional in Intermediate cardiovascular risk (n=260). Plasma LDL-cholesterol was evaluated on Coronary artery calcification (CAC) score =0 (OR 0.67, 95% CI 0.48-0.92, p=0.01). Plasma LDL-cholesterol was independently associated with CAC score =0 (OR 0.67; 95% CI 0.48-0.92), CAC score >100 (OR 1.59), and high femoral IMT (OR 1.89) in intermediate-risk individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: